Summit Trail Advisors LLC Increases Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Summit Trail Advisors LLC grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,714 shares of the medical equipment provider’s stock after purchasing an additional 152 shares during the quarter. Summit Trail Advisors LLC’s holdings in Intuitive Surgical were worth $2,097,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. One Wealth Management Investment & Advisory Services LLC grew its holdings in Intuitive Surgical by 3.4% during the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 23 shares during the period. Indiana Trust & Investment Management CO lifted its position in shares of Intuitive Surgical by 5.3% during the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after buying an additional 25 shares in the last quarter. Hoxton Planning & Management LLC grew its stake in shares of Intuitive Surgical by 4.9% during the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 25 shares during the period. First Affirmative Financial Network increased its holdings in Intuitive Surgical by 2.7% in the 2nd quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after acquiring an additional 26 shares in the last quarter. Finally, Moors & Cabot Inc. raised its stake in Intuitive Surgical by 2.3% during the 2nd quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock worth $516,000 after acquiring an additional 26 shares during the period. Institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of recent analyst reports. Evercore ISI dropped their price target on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Robert W. Baird lifted their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Piper Sandler increased their price target on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. JPMorgan Chase & Co. boosted their price objective on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Finally, Morgan Stanley upped their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $446.45.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,655,048.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Robert Desantis sold 188 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total transaction of $90,655.48. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,655,048.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock valued at $25,528,753 over the last ninety days. 0.90% of the stock is owned by insiders.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $486.20 on Friday. The stock has a market capitalization of $172.46 billion, a PE ratio of 87.76, a P/E/G ratio of 5.41 and a beta of 1.39. The company’s fifty day moving average is $468.01 and its 200 day moving average is $425.12. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the previous year, the firm posted $1.18 EPS. The business’s quarterly revenue was up 14.5% on a year-over-year basis. As a group, research analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.